This is a clinical trial of a drug called Baxdrostat on patients with treatment-resistant hypertension. The difference in the change in systolic blood pressure between the 2-mg group and the placebo group was −11.0 mm Hg (95% confidence interval [CI], −16.4 to −5.5; P<0.001), and the difference in this change between the 1-mg group and the placebo group was −8.1 mm Hg (95% CI, −13.5 to −2.8; P=0.003). No serious adverse events were reported and the drug was well-tolerated.
https://www.nejm.org/doi/full/10.1056/NEJMoa2213169?query=featured_cardiology
Leave a Reply